KOD - Regenxbio: Suprachoroidal Data May Impress
- Regenxbio (RGNX) has an internal gene therapy pipeline and also earns licensing revenue from partners using their IP.
- The internal pipeline and partner programs have progressed substantially.
- Regenxbio has a cash-rich balance sheet with $650 million.
- In Q3, Regenixbio will produce six-month data from Cohort 1 for RGX-314 administered using a suprachoroidal ("SCS") injector which may serve as a catalyst for the stock.
- There is very little value assigned to the flagship asset and appreciation in the RGNX share price is possible if favorable data is produced.
For further details see:
Regenxbio: Suprachoroidal Data May Impress